Phreesia Yönetim
Yönetim kriter kontrolleri 3/4
Phreesia CEO'su Chaim Indig, Jan2005 tarihinde atandı, in görev süresi 21.42 yıldır. in toplam yıllık tazminatı $ 8.26M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.2% maaş ve 93.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.32% ine doğrudan sahiptir ve bu hisseler $ 13.75M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 7.7 yıldır.
Anahtar bilgiler
Chaim Indig
İcra Kurulu Başkanı
US$8.3m
Toplam tazminat
| CEO maaş yüzdesi | 6.23% |
| CEO görev süresi | 21.4yrs |
| CEO sahipliği | 2.3% |
| Yönetim ortalama görev süresi | 3.3yrs |
| Yönetim Kurulu ortalama görev süresi | 7.7yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Jun 17
PHR: Cost Discipline And Profit Focus Will Support Stock Multiple Recovery
Analysts have trimmed their average price target on Phreesia stock by a few dollars into the low teens. This reflects concern that cost cutting is coming alongside reduced visibility on organic growth and rising competitive pressure in digital health advertising.Seeking Alpha • Jun 15
Phreesia: Rating Downgrade As Growth Outlook Worsens
Summary Phreesia is downgraded to Hold as profitability improves, but growth outlook becomes less compelling. PHR's EBITDA and free cash flow are rising, but revenue growth is slowing and increasingly reliant on acquired payments. Subscription revenue is declining, and organic payment solutions growth remains weak despite the AccessOne acquisition. Valuation is historically low; upside depends on evidence of organic growth and successful cross-selling of AccessOne. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 10
Phreesia's (NYSE:PHR) Performance Is Even Better Than Its Earnings Suggest
Phreesia, Inc.'s ( NYSE:PHR ) strong earnings report was rewarded with a positive stock price move. Our analysis found...Anlatı Güncellemesi • Jun 01
PHR: Cost Discipline And Higher Margins Will Support Multiple Recovery
Analysts have reduced their average price target for Phreesia by about $1, to roughly $14. Lower revenue growth expectations and multiple downgrades related to growth visibility and competitive pressures are only partly offset by improving profit margin assumptions and a lower projected P/E.Anlatı Güncellemesi • May 17
PHR: Post Reset Execution On Profitability And Intake Reach Will Support Multiple
Analysts have trimmed their fair value estimate for Phreesia from about $16.17 to $15.39 and lowered the future P/E assumption, reflecting a broad reset in price targets as firms point to slowing digital advertising growth and rising competition. Analyst Commentary Recent research points to a sharp reset in expectations for Phreesia, with multiple firms cutting price targets and, in several cases, downgrading ratings.Anlatı Güncellemesi • Apr 24
PHR: Post Guidance Reset Execution On Profitability And Intake Reach Will Support Multiple
The updated analyst price target for Phreesia reflects a modest downward adjustment of around $0.28, with analysts pointing to slightly lower assumptions for revenue growth, profit margin, and future P/E, along with a small change in the discount rate. Analyst Commentary Recent research updates on Phreesia have been concentrated on lowering price targets and, in several cases, revising ratings, which points to a clear reset in expectations around growth, profitability, and execution risk.Anlatı Güncellemesi • Apr 10
PHR: Profitability Focus And Intake Reach Will Support Post Guidance Reset Multiple Resilience
Analysts have reduced their average price target on Phreesia to reflect a lower fair value estimate of about $16.44, down from roughly $27.89. They cited more conservative assumptions for revenue growth, profit margins and future P/E multiples after a broad wave of target cuts and downgrades from multiple firms.Anlatı Güncellemesi • Mar 26
PHR: Profitability Focus And Intake Reach Will Support Future Multiple Resilience
Analyst price targets on Phreesia have been trimmed by a few dollars to around the mid $20s, as analysts factor in slightly lower revenue growth and profit margin assumptions while still using a relatively high future P/E of about 37x. Analyst Commentary Recent Street research on Phreesia has centered on fine tuning price targets and reassessing how much investors should pay for the company’s earnings profile, rather than making wholesale shifts in views on the business itself.Anlatı Güncellemesi • Mar 11
PHR: Profitability Pivot And Intake Network Breadth Will Support Future Margin Expansion
Analysts have trimmed their average price targets on Phreesia by roughly $5 to the mid $20s, reflecting a mix of caution after a challenging period for health tech stocks and continued confidence in the company’s profitability pivot and patient intake platform. Analyst Commentary Recent Street research on Phreesia clusters around a common theme, lower price targets but generally constructive views on the company’s execution and path to profitability.Anlatı Güncellemesi • Feb 24
PHR: Profitability Pivot And AccessOne Integration Will Drive Future Margin Expansion
The updated analyst price target for Phreesia reflects a modest trim of fair value to about $28.05, as analysts recalibrate their models following a series of target cuts to the $24 to $30 range. They continue to cite the company’s profitability pivot and patient intake platform scale as key parts of the long-term thesis.Anlatı Güncellemesi • Feb 10
PHR: Profitability Pivot And AccessOne Integration Will Support Future Margin Expansion
Analysts have nudged their price targets on Phreesia slightly lower, trimming fair value estimates by about $0.32 to reflect modestly updated assumptions on discount rates, margins, and future P/E. At the same time, recent research highlights both reduced targets in health tech and continued optimism around the company’s patient intake and payments platform.Anlatı Güncellemesi • Jan 26
PHR: Profitability Pivot And AccessOne Synergies Will Support Future EBITDA Improvement
Analysts have nudged their fair value estimate for Phreesia slightly lower to about $28.63 per share, reflecting modestly softer assumptions for revenue growth, profit margins, and future P/E multiples following a series of recent price target cuts and fresh coverage initiations. Analyst Commentary Recent research paints a mixed picture for Phreesia, with several firms trimming price targets while others initiate or resume positive ratings.Anlatı Güncellemesi • Jan 12
PHR: Profitability Pivot And AccessOne Integration Will Support Future Margin Expansion
Analysts trimmed their fair value estimate for Phreesia to about $29.16 from $29.82 and lowered future P/E assumptions, pointing to reduced Street price targets in the mid $20s, even as research notes highlight the company’s profitability focus, margin progress, and reach across U.S. patient visits. Analyst Commentary Street research on Phreesia is mixed, with several firms trimming price targets while still highlighting profitability efforts, margin progress, and the scale of the platform across U.S. patient visits.Anlatı Güncellemesi • Dec 24
PHR: Cross Sell And AccessOne Integration Will Drive Future EBITDA Expansion
Narrative Update Analysts have modestly trimmed their price target on Phreesia to approximately $29.82 from about $32.12 per share, reflecting slightly lower assumptions for revenue growth and profit margins even as they highlight the company’s growing cross-sell traction, long-term lift from the pending AccessOne acquisition, and potential for significant operating leverage to drive EBITDA growth in the high-20s to low-30s percentage range. Analyst Commentary Analysts generally view Phreesia positively, with recent coverage initiating the stock with an Outperform rating and a price target modestly above current levels, citing a strengthening growth and profitability profile.Anlatı Güncellemesi • Dec 10
PHR: Cross Selling Momentum Will Drive Stronger Long Term EBITDA Expansion
Analysts have modestly reduced their price target on Phreesia from $33.73 to $32.12 per share, citing expectations for stronger long term EBITDA growth supported by cross selling traction and operating leverage, as well as incremental upside from the pending AccessOne acquisition. Analyst Commentary Analysts highlight that Phreesia's current valuation reflects confidence in its ability to execute on growth initiatives while expanding margins, but they also caution that the shares already price in a meaningful portion of the long term opportunity.Analiz Makalesi • Sep 27
Phreesia, Inc.'s (NYSE:PHR) 26% Cheaper Price Remains In Tune With Revenues
Phreesia, Inc. ( NYSE:PHR ) shareholders won't be pleased to see that the share price has had a very rough month...Anlatı Güncellemesi • Sep 06
AI Integration And Digital Adoption Will Expand Healthcare Services
Phreesia’s price target increased to $33.73 as analysts responded positively to solid Q2 results, upwardly revised FY26 EBITDA guidance, strategic product launches, and the AccessOne acquisition—despite valuation concerns—supporting a strong double-digit growth outlook and margin expansion. Analyst Commentary Solid Q2 results, with revenues in line and adjusted EBITDA ahead of consensus; company raised FY26 EBITDA guidance driven by effective expense management.Yeni Anlatı • May 27
Digital Healthcare Tools Will Expand Market Reach
Expanding digital adoption and data-driven solutions are driving operational efficiency, deeper client relationships, and long-term recurring revenue growth.Analiz Makalesi • Apr 29
Revenues Tell The Story For Phreesia, Inc. (NYSE:PHR)
There wouldn't be many who think Phreesia, Inc.'s ( NYSE:PHR ) price-to-sales (or "P/S") ratio of 3.4x is worth a...Analiz Makalesi • Mar 07
Why Phreesia, Inc. (NYSE:PHR) Could Be Worth Watching
Phreesia, Inc. ( NYSE:PHR ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in...Analiz Makalesi • Feb 14
Phreesia (NYSE:PHR) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Dec 27
Phreesia, Inc.'s (NYSE:PHR) Shares Climb 27% But Its Business Is Yet to Catch Up
Phreesia, Inc. ( NYSE:PHR ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Dec 12
Phreesia Has Turned The Corner, Can It Continue To Mend?
Summary Phreesia’s Q3 earnings show solid revenue growth, but customer growth is decelerating, impacting overall performance. Fiscal 2025 guidance improved with higher EBITDA and tighter revenue estimates, while fiscal 2026 projects slower revenue growth but significant EBITDA improvement. Strong cash flow and disciplined expense management are encouraging, with the company maintaining positive cash flows and holding $82M in cash. Despite current trading challenges, Phreesia’s innovative healthcare solutions and partnerships position it well for future growth and potential valuation recovery. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 07
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues
With a price-to-sales (or "P/S") ratio of 3.1x Phreesia, Inc. ( NYSE:PHR ) may be sending bearish signals at the...Analiz Makalesi • Oct 08
Is Phreesia (NYSE:PHR) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Sep 06
Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results
Phreesia, Inc. ( NYSE:PHR ) last week reported its latest second-quarter results, which makes it a good time for...Seeking Alpha • Sep 05
Phreesia: Remain Bullish Given The Healthy Growth Outlook
Summary I maintain a buy rating for PHR, driven by strong client growth, solid revenue outlook, and increasing transaction sizes in the pipeline. PHR's 2Q25 results show 19% y/y revenue growth and improved profitability, with positive EBITDA and FCF, indicating strong financial health. Despite a slight decline in revenue per AHSC, larger client acquisitions and increased transaction sizes support my 20% growth expectation. Read the full article on Seeking AlphaAnaliz Makalesi • Jul 18
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 26% Higher
Phreesia, Inc. ( NYSE:PHR ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Jun 06
Phreesia: Growth Remains Strong, With EBITDA Margin Set To Improve
Summary Phreesia's revenue grew 20.7% year-over-year, with subscription revenue growing 23.4% and payment processing revenue growing 11.6%. The company added 103 new clients in the quarter, beating guidance, and expects to add around 100 more in the next quarter. Phreesia's focus on profitability is showing positive results, with EBITDA margin expanding and guidance suggesting further improvement. Read the full article on Seeking AlphaAnaliz Makalesi • May 25
The Price Is Right For Phreesia, Inc. (NYSE:PHR)
When close to half the companies in the Healthcare Services industry in the United States have price-to-sales ratios...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Apr 30 2026 | n/a | n/a | US$9m |
| Jan 31 2026 | US$8m | US$515k | US$2m |
| Oct 31 2025 | n/a | n/a | -US$5m |
| Jul 31 2025 | n/a | n/a | -US$24m |
| Apr 30 2025 | n/a | n/a | -US$43m |
| Jan 31 2025 | n/a | n/a | -US$59m |
| Oct 31 2024 | n/a | n/a | -US$83m |
| Jul 31 2024 | n/a | n/a | -US$100m |
| Apr 30 2024 | n/a | n/a | -US$119m |
| Jan 31 2024 | US$8m | US$495k | -US$137m |
| Oct 31 2023 | n/a | n/a | -US$144m |
| Jul 31 2023 | n/a | n/a | -US$152m |
| Apr 30 2023 | n/a | n/a | -US$162m |
| Jan 31 2023 | US$8m | US$515k | -US$176m |
| Oct 31 2022 | n/a | n/a | -US$185m |
| Jul 31 2022 | n/a | n/a | -US$181m |
| Apr 30 2022 | n/a | n/a | -US$158m |
| Jan 31 2022 | US$9m | US$515k | -US$118m |
| Oct 31 2021 | n/a | n/a | -US$80m |
| Jul 31 2021 | n/a | n/a | -US$50m |
| Apr 30 2021 | n/a | n/a | -US$32m |
| Jan 31 2021 | US$6m | US$419k | -US$27m |
| Oct 31 2020 | n/a | n/a | -US$23m |
| Jul 31 2020 | n/a | n/a | -US$19m |
| Apr 30 2020 | n/a | n/a | -US$83m |
| Jan 31 2020 | US$10m | US$346k | -US$91m |
Tazminat ve Piyasa: Chaim 'nin toplam tazminatı ($USD 8.26M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.46M ).
Tazminat ve Kazançlar: Chaim 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Chaim Indig (47 yo)
21.4yrs
Görev süresi
US$8,262,693
Tazminat
Mr. Chaim Indig co-founded Phreesia, Inc. in January 2005 and serves as Chief Executive Officer and Director since January 2005. Mr. Indig has helped to revolutionize the patient check-in experience. Under...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 21.4yrs | US$8.26m | 2.32% $ 13.7m | |
| Co-Founder & President of Provider Solutions | 21.4yrs | US$3.66m | 1.14% $ 6.8m | |
| Chief Financial Officer | 3.3yrs | US$3.66m | 0.031% $ 186.5k | |
| General Counsel & Secretary | 5.8yrs | US$2.65m | 0.077% $ 454.8k | |
| President of Network Solutions | 7.3yrs | US$3.63m | 0.15% $ 913.7k | |
| Senior VP & Chief Accounting Officer | less than a year | Veri yok | 0.039% $ 229.3k | |
| Chief Technology Officer | 2.3yrs | Veri yok | Veri yok | |
| Vice President of Marketing | no data | Veri yok | Veri yok | |
| Senior Vice President of Human Resources | 16.2yrs | Veri yok | 0.27% $ 1.6m | |
| Chief Information Security Officer | 1.4yrs | Veri yok | Veri yok | |
| Senior Vice President of Product | less than a year | Veri yok | Veri yok | |
| Senior Vice President of Provider Sales | less than a year | Veri yok | Veri yok |
3.3yrs
Ortalama Görev Süresi
47yo
Ortalama Yaş
Deneyimli Yönetim: PHR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 21.4yrs | US$8.26m | 2.32% $ 13.7m | |
| Board Observer | no data | Veri yok | Veri yok | |
| Independent Director | 18.7yrs | US$222.43k | 0.11% $ 629.2k | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 5.9yrs | US$224.93k | 0.083% $ 490.9k | |
| Independent Director | 7.1yrs | US$247.43k | 0.076% $ 449.0k | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 7.7yrs | US$234.99k | 0.0099% $ 58.6k |
7.7yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: PHR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.7 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/25 17:39 |
| Gün Sonu Hisse Fiyatı | 2026/06/25 00:00 |
| Kazançlar | 2026/04/30 |
| Yıllık Kazançlar | 2026/01/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Phreesia, Inc. 23 Bu analistlerden 18, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Joseph Vruwink | Baird |
| Glen Santangelo | Barclays |
| Zhilin Long | Berenberg |